Disparities in access to opioid treatment programs and buprenorphine providers by race and ethnicity in the contiguous US

被引:9
|
作者
Amiri, Solmaz [1 ,4 ]
Panwala, Victoria [2 ]
Amram, Ofer [3 ]
机构
[1] Washington State Univ, Inst Res & Educ Adv Community Hlth IREACH, Elson S Floyd Coll Med, Seattle, WA USA
[2] Washington State Univ, Elson S Floyd Coll Med, Seattle, WA USA
[3] Washington State Univ, Elson S Floyd Coll Med, Dept Nutr & Exercise Physiol, Spokane, WA USA
[4] Washington State Univ, Elson S Floyd Coll Med, Inst Res & Educ Adv Community Hlth IREACH, 1100 Olive Way,Ste 1200, Seattle, WA 98101 USA
来源
JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT | 2024年 / 156卷
关键词
ALASKA NATIVES; PRIMARY-CARE; CANCER CARE; METHADONE TREATMENT; AREA DEPRIVATION; UNITED-STATES; USE DISORDER; MORTALITY; MAINTENANCE; HOSPITALS;
D O I
10.1016/j.josat.2023.209193
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: The burden of drug overdose mortality varies by race and ethnicity, with American Indian/Alaska Native (AI/AN), Black, and White people experiencing the largest burden. We analyzed census block group data to evaluate differences in travel distance to opioid treatment programs (OTP) and buprenorphine providers by race and ethnicity. Methods: The Substance Abuse and Mental Health Services Administration provided the addresses of OTPs and buprenorphine providers. The study classified block groups as majority (>= 50 %) AI/AN, Black, Asian, White, no single racial majority, or Hispanic. We classified deprivation and rurality using the Area Deprivation Index and Rural-Urban Commuting Area codes. The study applied generalized linear mixed models. Results: Among all block groups, the median road distance to the nearest OTPs and buprenorphine providers was 8 and 2 miles, respectively. AI/AN-majority block groups had the longest median distances to OTPs (88 miles versus 4-10 miles) and buprenorphine providers (17 miles versus 1-3 miles) compared to other racial or ethnic majority block groups. For OTPs and buprenorphine providers, travel distances were slightly greater in more deprived block groups compared to less deprived block groups. The median distance to the nearest OTPs and buprenorphine providers were larger in micropolitan and small town/rural block groups compared to metropolitan areas. Conclusions: Disparities exist in travel distance to OTPs and buprenorphine providers. People in block groups with AI/AN-majority, nonmetropolitan, or more deprived designation experience travel disparities accessing treatment. Future research should develop targeted interventions to reduce access to care disparities for individuals with opioid use disorder.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Disparities in air pollution attributable mortality in the US population by race/ethnicity and sociodemographic factors
    Geldsetzer, Pascal
    Fridljand, Daniel
    Kiang, Mathew V.
    Bendavid, Eran
    Heft-Neal, Sam
    Burke, Marshall
    Thieme, Alexander H.
    Benmarhnia, Tarik
    NATURE MEDICINE, 2024, 30 (07) : 2092 - 2092
  • [42] Medicaid prevalence and opioid use disorder treatment access disparities
    Richards, Michael R.
    Leech, Ashley A.
    Stein, Bradley D.
    Buntin, Melinda B.
    Patrick, Stephen W.
    HEALTH SERVICES RESEARCH, 2022, 57 (02) : 422 - 429
  • [43] Private Equity Ownership of US Opioid Treatment Programs
    Zhu, David T.
    Song, Zirui
    Kannan, Sneha
    Cai, Christopher L.
    Bajaj, Simar S.
    Gondi, Suhas
    JAMA PSYCHIATRY, 2025, 82 (02) : 204 - 206
  • [44] Race, ethnicity, and pain treatment: Striving to understand the causes and solutions to the disparities in pain treatment
    Bonham, VL
    JOURNAL OF LAW MEDICINE & ETHICS, 2001, 29 (01): : 52 - +
  • [45] Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments
    Pletcher, Mark J.
    Kertesz, Stefan G.
    Kohn, Michael A.
    Gonzales, Ralph
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (01): : 70 - 78
  • [46] Impact of US Opioid Drug Overdose by Race/Ethnicity and State in 2005-2017
    Zhu, Alicia
    Li, Yuemeng
    Le, Austin
    Xu, Jane
    Singh, Jaiveer
    Srinivasan, Malathi
    Palaniappan, Latha P.
    Long, Jin
    Gross, Eric R.
    ANESTHESIA AND ANALGESIA, 2022, 134 : 712 - 714
  • [47] Injectable Buprenorphine: An Opportunity to Improve Treatment Access for Youth With Opioid Use Disorder
    Calihan, Jessica B.
    Bagley, Sarah M.
    JOURNAL OF ADOLESCENT HEALTH, 2024, 75 (01) : 13 - 14
  • [48] Improving Access to Pediatric Opioid Use Disorder Treatment With Buprenorphine Waiver Training
    Bayner, Jessica
    Ignaszewski, Martha
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (03): : 240 - 241
  • [49] Comparing Two Databases to Identify Access to Buprenorphine Treatment for Opioid Use Disorder
    Anyanwu, Precious
    Varisco, Tyler J.
    Wanat, Matthew A.
    Bapat, Shweta
    Claborn, Kasey
    Thornton, J. Douglas
    JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2022, 36 (02) : 103 - 111
  • [50] Access to treatment before and after Medicare coverage of opioid treatment programs
    Liu, Ruijie
    Beetham, Tamara
    Newton, Helen
    Busch, Susan H.
    HEALTH AFFAIRS SCHOLAR, 2024, 2 (06):